Priothera Limited
Priothera is developing the orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies.
Total raised
€30M
€30,000,000
Funding rounds
1
Investors
4
distinct backers
Active since
2020-10
latest 2020-10
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood16
base rate 44% for Series A
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-10-14 | Series A | €30M | Earlybird Venture Capital,Fountain Healthcare Partners,HealthCap,Tekla Capital Management | View deal → |
Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Wayflyer€2.1BIreland · E-commerce
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Oura Health€779MFinland · Healthtech